MECP2, methyl-CpG binding protein 2, 4204

N. diseases: 664; N. variants: 387
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 Biomarker disease CTD_human It indicates that MeCP2 may be an attractive target for human HCC. 26189965 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 Biomarker disease BEFREE It indicates that MeCP2 may be an attractive target for human HCC. 26189965 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 Biomarker disease BEFREE Our findings demonstrated that MeCP2 promoted the proliferation of human HCC HepG2 cells with activation of ERK1/2 signaling pathways, suggesting a novel mechanism for pharmacological study of treatment for human HCC. 24199952 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 Biomarker disease BEFREE Administration of zinc-binding protein-89 downregulated histone deacetylase 3 expression and suppressed the activities of histone deacetylase and deoxyribonucleic acid methyltransferase, which led to maintenance of histone acetylation status, inhibited the binding of methyl-CpG-binding protein 2 to genomic deoxyribonucleic acid and demethylated CpG islands in the Bak promoter in hepatocellular carcinoma cells. 23954442 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 Biomarker disease RGD A chromatin immunoprecipitation assay demonstrated that MeCP2 was associated with the MT-I promoter in the hepatoma implicating its involvement in repressing the methylated promoter. 11844796 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.540 AlteredExpression disease BEFREE Slightly reduced expression of MBD2 was detected in HCCs, and the expression of MeCP2 was particularly reduced in HCCs with portal vein involvement. 11230735 2001